title: Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care.
abstract: The Institute for Pharmacogenomics and Individualized Therapy (IPIT) at the University of North Carolina at Chapel Hill (NC, USA) is a collaborative, multidisciplinary unit that brings together faculty from different disciplines and crosses the traditional departmental/school structure to perform pharmacogenomics research. IPIT investigators work together towards the goal of developing therapies to enable the delivery of individualized medical care. The NIH-supported Comprehensive Research on Expressed Alleles in Therapeutic Evaluation (CREATE) group leads the field in the evaluation of pathways regulating drug activity, and also provides a foundation for future IPIT research. IPIT members perform bench research, clinical cohort analysis and prospective clinical intervention studies, research on the integration of pharmacogenomic therapy into practice and research to foster global health pharmacogenomics application through the Pharmacogenetics for Every Nation Initiative. IPIT Investigators are actively incorporating a pharmacogenomics curriculum into existing teaching programs at all levels.
authors.affiliation: UNC Institute for Pharmacogenomics & Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7361, USA.
authors.forename: Tejinder K
authors.initials: TK
authors.lastname: Rakhra-Burris
authors.forename: J Todd
authors.initials: JT
authors.lastname: Auman
authors.forename: Patricia
authors.initials: P
authors.lastname: Deverka
authors.forename: Lynn G
authors.initials: LG
authors.lastname: Dressler
authors.forename: James P
authors.initials: JP
authors.lastname: Evans
authors.forename: Richard M
authors.initials: RM
authors.lastname: Goldberg
authors.forename: Tammy M
authors.initials: TM
authors.lastname: Havener
authors.forename: Janelle M
authors.initials: JM
authors.lastname: Hoskins
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Jonas
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Long
authors.forename: Alison A
authors.initials: AA
authors.lastname: Motsinger-Reif
authors.forename: William J
authors.initials: WJ
authors.lastname: Irvin
authors.forename: Kristy L
authors.initials: KL
authors.lastname: Richards
authors.forename: Mary W
authors.initials: MW
authors.lastname: Roederer
authors.forename: John M
authors.initials: JM
authors.lastname: Valgus
authors.forename: Marcia van
authors.initials: Mv
authors.lastname: Riper
authors.forename: John A
authors.initials: JA
authors.lastname: Vernon
authors.forename: William C
authors.initials: WC
authors.lastname: Zamboni
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Wagner
authors.forename: Christine M
authors.initials: CM
authors.lastname: Walko
authors.forename: Karen E
authors.initials: KE
authors.lastname: Weck
authors.forename: Tim
authors.initials: T
authors.lastname: Wiltshire
authors.forename: Howard L
authors.initials: HL
authors.lastname: McLeod
mesh_terms: D000047:Academies and Institutes; D035843:Biomedical Research; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D008967:Molecular Biology; D009657:North Carolina; D010597:Pharmacogenetics / Q000193:education; D057285:Precision Medicine; D034741:RNA, Small Interfering; D016032:Randomized Controlled Trials as Topic; D013629:Tamoxifen / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D034741:RNA, Small Interfering; D013629:Tamoxifen; D014859:Warfarin